Astellas Pharma's R&D expenditure FY 2014-2023
In fiscal year 2023, the value of Astellas Pharma's research and development expenditures amounted to more than 294 billion Japanese yen, the highest number of the past decade. Within the observed period, R&D spending increased steadily almost every year, starting at approximately 206 billion yen in fiscal 2014.
The priority areas of Astellas research and development include infectious diseases, diabetes, and gastrointestinal diseases.